CNSP
CNS Pharmaceuticals, Inc.
Key Financials
Operating Income
$-15986559
↓ 7.3%
Net Income
$-15850564
↓ 6.7%
Total Assets
$8.6M
↓ 0.9%
Total Liabilities
$4.1M
↑ 62.5%
EPS (Diluted)
$-35.75
↑ 8.0%
Cash & Equivalents
$7.2M
↑ 11.4%
Shareholders' Equity
$4.5M
↓ 26.8%
Operating Cash Flow
$-13811107.00
↑ 19.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/18/2026 | View on SEC |
| 3 | 8/18/2026 | View on SEC |
| 4 | 8/18/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 7/2/2026 | View on SEC |
| EFFECT | 5/26/2026 | View on SEC |
| 424B3 | 5/26/2026 | View on SEC |
| CORRESP | 5/22/2026 | View on SEC |
| UPLOAD | 5/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CNSP |
| Company Name | CNS Pharmaceuticals, Inc. |
| CIK | 1729427 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 1-800-946-9185 |